CytRx, the parent firm of RNAi drugs developer RXi Pharmaceuticals,has named Mitchell Fogelman as its new CFO.
Fogelman replaces Matthew Natalizio who CytRx said left to “pursue other opportunities.”
Fogelman has held positions with International Aluminum, an industrial products maker, and accounting firm PricewaterhouseCoopers.
He holds an MBA and BA from the University of California, Los Angeles.
Cepheid, a molecular diagnostics firm, has appointed Ohio State University professor and microRNA researcher Carlo Croce to its scientific advisory board.